Q2 EPS Forecast for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research reduced their Q2 2026 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, June 2nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $1.72 per share for the quarter, down from their previous forecast of $1.78. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $7.60 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2026 earnings at $2.39 EPS, FY2026 earnings at $7.56 EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $2.04 EPS, Q3 2027 earnings at $2.26 EPS, Q4 2027 earnings at $2.88 EPS, FY2027 earnings at $8.96 EPS, Q1 2028 earnings at $2.03 EPS and FY2028 earnings at $10.21 EPS.

A number of other equities analysts have also commented on HALO. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Finally, HC Wainwright increased their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $69.82 on Thursday. The company’s fifty day moving average price is $66.44 and its 200-day moving average price is $68.71. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 0.27 and a beta of 0.88. Halozyme Therapeutics has a one year low of $51.06 and a one year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in HALO. Empowered Funds LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $195,000. Hsbc Holdings PLC boosted its position in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC boosted its position in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares during the period. Finally, Baird Financial Group Inc. boosted its position in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 122,107 shares of company stock valued at $8,254,834. Insiders own 2.50% of the company’s stock.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, suggesting improving profit expectations for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts now see stronger earnings in several quarters, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which may reinforce the stock’s valuation outlook. Halozyme Therapeutics article
• Neutral Sentiment: There was also a small increase in one near-term estimate for Q4 2026, while Q2 2026 was trimmed slightly and Q1 2028 was revised lower, indicating a mostly constructive but not uniformly higher forecast profile. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were executed under pre-arranged 10b5-1 plans, which usually makes them less concerning to investors than discretionary selling. Halozyme Therapeutics article

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.